Castle Biosciences, Inc.
CSTL
$24.06
$0.502.12%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 86.19M | 87.99M | 86.31M | 85.78M | 87.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 86.19M | 87.99M | 86.31M | 85.78M | 87.00M |
| Cost of Revenue | 17.63M | 16.38M | 16.18M | 15.61M | 14.52M |
| Gross Profit | 68.56M | 71.61M | 70.13M | 70.17M | 72.48M |
| SG&A Expenses | 58.07M | 58.62M | 49.97M | 50.50M | 51.09M |
| Depreciation & Amortization | 1.96M | 28.33M | 4.34M | 2.27M | 2.25M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.44M | 115.92M | 82.26M | 80.70M | 81.99M |
| Operating Income | -4.25M | -27.93M | 4.05M | 5.08M | 5.01M |
| Income Before Tax | -143.00K | -26.27M | 7.89M | 8.28M | 7.89M |
| Income Tax Expenses | -4.67M | -423.00K | -1.71M | 6.01M | -1.03M |
| Earnings from Continuing Operations | 4.52M | -25.85M | 9.59M | 2.27M | 8.92M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.52M | -25.85M | 9.59M | 2.27M | 8.92M |
| EBIT | -4.25M | -27.93M | 4.05M | 5.08M | 5.01M |
| EBITDA | -837.00K | 1.84M | 9.82M | 8.62M | 8.36M |
| EPS Basic | 0.16 | -0.90 | 0.34 | 0.08 | 0.32 |
| Normalized Basic EPS | -0.03 | -0.54 | 0.16 | 0.19 | 0.18 |
| EPS Diluted | 0.15 | -0.90 | 0.31 | 0.08 | 0.31 |
| Normalized Diluted EPS | -0.03 | -0.54 | 0.15 | 0.18 | 0.17 |
| Average Basic Shares Outstanding | 28.91M | 28.61M | 28.13M | 27.84M | 27.65M |
| Average Diluted Shares Outstanding | 29.55M | 28.61M | 30.20M | 29.40M | 28.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |